A case report describing durable tumor shrinkage from ALK inhibition in gastric cancer with a low-frequency SPTBN1–ALK fusion and later lineage-driven resistance.
Key Takeaways
- Tumor was negative for HER2 amplification, microsatellite instability, and PD-L1 expression
- Accompanied by expansion of TP53-mutant alleles and acquisition of additional genomic alterations
- Subsequent histologic transformation to small-cell neuroendocrine carcinoma was observed